Dr. Charles Dinarello, Chief Scientific Officer of Omni Bio, is a co-author of an article that is now available in the journal Blood, which is the premier journal of the American Society of Hematology (ASH).  The paper describes the use of Alpha‑1 antitrypsin (AAT) to treat mice with a lethal form of rejection of bone marrow transplantation.  Mice survive the crisis with AAT treatment.  The paper clearly proposes that because of the long-term safety of AAT clinical trials in humans could be started.  Omni Bio has a patent pending for the use of AAT to treat bone marrow transplantation dating.  Omni Bio announced in February 2011 that it had letters of intent to use AAT for transplantation.  Omni Bio is currently negotiating with medical centers in the U.S. and Europe to begin clinical trials.

Watch Dr. Dinarello’s comments on the article in Blood, specifically the research of AAT in the area of bone marrow transplants and Graft vs. Host Disease (GVHD).

A link to the abstract version of the article is available here:

http://bloodjournal.hematologylibrary.org/content/early/2011/09/06/blood-2011-07-365247.abstract?sid=7e5e7972-8a66-47a9-97c9-3401d8a280ce

Full text of the article is available only to subscribers of Blood. Login and account creation is available here:

Blood, the official journal of the American Society of Hematology (ASH), has been selected by the Special Libraries Association (SLA) as one of the top 100 most influential research journals of biology and medicine over the past 100 years.